Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study

RCT (n=180) found longer overall survival with durvalumab & tremelimumab vs standard of care (6.6 vs 4.1 months, HR for death 0.72, 90%CI 0.54-0.97). There was no difference in PFS, and grade 3 ADRs were more frequent with immunotherapy (64% vs 20%)

SPS commentary:

A related commentary discusses this research


JAMA Oncology

Resource links: